Applied Therapeutics ( (APLT) ) has released its Q1 earnings. Here is a breakdown of the information Applied Therapeutics presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Applied Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformative treatments for rare diseases, with its lead drug candidate being govorestat, aimed at treating CNS rare metabolic diseases. In its latest earnings report for the first quarter of 2025, the company highlighted its ongoing efforts to advance govorestat across multiple indications, including CMT-SORD and Classic Galactosemia, and announced upcoming presentations of clinical data at the Peripheral Nerve Society 2025 Annual Meeting.
The company reported a decrease in cash and cash equivalents to $50.8 million as of March 31, 2025, from $79.4 million at the end of 2024. Research and development expenses decreased to $7.8 million, while general and administrative expenses increased to $17.7 million for the quarter. Notably, the net loss for the first quarter of 2025 was significantly reduced to $21.8 million compared to $83.9 million in the same period of 2024.
Applied Therapeutics continues to progress with its govorestat development programs, addressing regulatory feedback and exploring potential accelerated approval pathways with the FDA. The company remains focused on its strategic goals and is preparing for potential regulatory interactions for its drug candidates.
Looking ahead, Applied Therapeutics is optimistic about its strategic direction and the potential of govorestat to meet the unmet needs of patients with rare diseases. The management believes that with a strong team and focused efforts, the company is well-positioned to advance its priorities and achieve its clinical and regulatory objectives.